Key Points- Sales of the Alzheimer’s drug Leqembi may be slow initially due to logistical requirements but could pick up in 2024, analysts said.- Wall Street is chewing over the Food and Drug Administration’s Thursday approval of Biogen and Eisai’s Leqembi.- It’s the first medicine proven to slow the progression of Alzheimer’s in people at […]
